Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | RECQL | P46063 | 2/20 | 0.45 |
| ▸ | CASP3 | P42574 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1363991 | 0.85 | MAPT (0.40) | KMT2AMAPTRECQLCASP3SMN1; SMN2 | |
| SCHEMBL7981998 | 0.80 | RECQL (0.45) | KMT2AMAPTRECQLCASP3SMN1; SMN2 | |
| SCHEMBL22343845 | 0.79 | KMT2A (0.56) | KMT2AMAPTRECQLCASP3SMN1; SMN2 | |
| SCHEMBL2258501 | 0.78 | KMT2A (0.70) | KMT2AMAPTRECQLCASP3SMN1; SMN2 | |
| SCHEMBL16881234 | 0.76 | MAPT (0.41) | KMT2AMAPTRECQLCASP3SMN1; SMN2 | |
| SCHEMBL21744527 | 0.76 | MAPT (0.44) | KMT2AMAPTRECQLCASP3SMN1; SMN2 | |
| SCHEMBL11942311 | 0.74 | IDO1 (0.38) | — | |
| SCHEMBL12903756 | 0.74 | HPGD (0.51) | KMT2AMAPTCASP3SMN1; SMN2TSHR | |
| SCHEMBL3825680 | 0.73 | HSD17B10 (0.44) | KMT2AMAPTRECQLPKMTSHR | |
| SCHEMBL501378 | 0.73 | MRGPRX4 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1304324-B1 | SEROTONIN REUPTAKE INHIBITORS | DAINIPPON SUMITOMO PHARMA CO (JP) | 2007-10-03 | — | — | EP | disclosed |
| EP-1408962-B1 | SUBSTITUTED ISOINDOLES AND THE USE THEREOF | BAYER HEALTHCARE AG (DE) | 2006-03-15 | — | — | EP | disclosed |
| US-6933295-B2 | Substituted isoindoles and the use thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2005-08-23 | — | — | US | disclosed |
| US-20050004207-A1 | Nitrogen compounds such as N-(2-{4-[2-Amino-2-(hydroxyimino)ethyl]benzyl}-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl)-5-chloro-2-thiophenecarboxamide, used as blood-coagulation factor Xa antogonists for prophylaxis of cardiovascular disorders | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-01-06 | — | — | US | disclosed |
| US-6787560-B2 | PSYCHOLOGICAL DISORDERS; ANTIDEPRESSANTS | SUMITOMO PHARMACEUTICALS COMPANY LIMITED (JP) | 2004-09-07 | — | — | US | disclosed |
| EP-1408962-A1 | SUBSTITUTED ISOINDOLES AND THE USE THEREOF | Bayer HealthCare AG (DE) | 2004-04-21 | — | — | EP | disclosed |
| US-20030191126-A1 | Psychological disorders; antidepressants | SUMITOMO PHARMACEUTICALS COMPANY LIMITED | 2003-10-09 | — | — | US | disclosed |
| EP-1304324-A1 | SEROTONIN REUPTAKE INHIBITORS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2003-04-23 | — | — | EP | disclosed |
| WO-2003007942-A1 | SUBSTITUTED ISOINDOLES AND THE USE THEREOF | BAYER HEALTHCARE AG (DE) | 2003-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191126-A1 | Psychological disorders; antidepressants | CRH, HTR2C, HTR1A | KMT2A 204/4885MAPT 1516/4885RECQL 2355/4885 |
| US-20050004207-A1 | Nitrogen compounds such as N-(2-{4-[2-Amino-2-(hydroxyimino)ethyl]benzyl}-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl)-5-chloro-2-thiophenecarboxamide, used as blood-coagulation factor Xa antogonists for prophylaxis of cardiovascular disorders | F2, SERPINC1, F11 | KMT2A 2610/4885MAPT 4734/4885RECQL 1618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.